Clinical Study

Safety and Feasibility of Repeated Intrathecal Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells in Patients with Neurological Diseases

Table 10

Comparison of adverse events among clinical studies of intrathecal autologous MSCs, allogeneic MSCs, and non-MSCs stem cells.

Adverse events (person-time)Autologous MSCs (%)
Allogeneic MSCs (%)
Non-MSCs stem cells (%)

Headache73 (7.10)10 (2.48)a111 (8.94)b
Dizziness0 (0.00)8 (1.98)a0 (0.00)b
Fever81 (7.88)8 (1.98)a109 (8.78)b
Nausea10 (0.97)2 (0.50)18 (1.45)
Pain at puncture site75 (7.30)7 (1.73)a26 (2.10)a
Neck pain2 (0.19)1 (0.25)0 (0.00)

a compared with autologous MSCs. b compared with allogeneic MSCs.